Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer | NEJM
MET Expression in Non-Small-Cell Lung Cancer: Testing, Treatment, and Future Directions This program is supported by an educational grant from. - ppt download
c-Met inhibitor - Wikipedia
A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations - Santarpia - Translational Lung Cancer Research
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer | Journal of Hematology & Oncology | Full Text
Inhibition of c-Met in NSCLC. A, inhibition of c-Met protein expression... | Download Scientific Diagram
Is there a place for crizotinib in c-MET alterations? A case of efficacy in ALK positive NSCLC patient with secondary c-MET amplification - Annals of Oncology
Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer | Clinical Cancer Research
MET Inhibition in Non-Small Cell Lung Cancer - European Medical Journal
MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregula | OTT
Active or Recent Clinical Trials of hepatocyte growth factor (HGF)-MET... | Download Table
Synergistic antitumor activity of low-dose c-Met tyrosine kinase inhibitor and sorafenib on human non-small cell lung cancer cells
Current Modalities in the Treatment of Lung Cancer
MET Expression in Non-Small-Cell Lung Cancer: Testing, Treatment, and Future Directions This program is supported by an educational grant from. - ppt download
FDA Approves TEPMETKO® as the First and Only Once-daily Oral MET Inhibitor for Patients with Metastatic NSCLC with METex14 Skipping Alterations
Alterations in the PI3K Pathway Drive Resistance to MET Inhibitors in NSCLC Harboring MET Exon 14 Skipping Mutations - Journal of Thoracic Oncology
Safety and Tolerability of c-MET Inhibitors in Cancer | SpringerLink
Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro - Journal of Thoracic Oncology
MET inhibition in lung cancer - Menis - Translational Lung Cancer Research
Met Inhibitors in Clinical Trials•
Novartis investigational lung cancer therapy capmatinib (INC280) granted FDA Breakthrough Therapy Designation for patients with MET-mutated advanced non-small cell lung cancer | Novartis
Targeting MET in Lung Cancer: Will Expectations Finally Be MET? - Journal of Thoracic Oncology
c-Met inhibitor - Wikipedia
